Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
100.0%
暂无批准数据
- Biotech venture financing increased 70.9% from $1.8 billion in Q2 2025 to $3.1 billion in Q3 2025, indicating potential market recovery. - Series D funding rounds experienced the highest growth, rising 60-fold to $832 million, reflecting investor focus on later-stage companies. - Kriya Therapeutics secured the largest Q3 financing round with $320 million for gene therapy development, while M&A activity increased 36.7%. - Sustained recovery depends on the sector's ability to navigate Trump administration policies and continued Federal Reserve interest rate cuts.
- Odyssey Therapeutics closed an oversubscribed $213 million Series D financing round to accelerate development of its autoimmune and inflammatory disease treatments after abandoning IPO plans in June. - The funding will support clinical trials for lead candidate OD-07656, a RIPK2-targeting small molecule in Phase II trials for ulcerative colitis and Crohn's disease. - The round included all existing investors plus new backers including Lightspeed Ventures, Jeito Capital, and TPG Life Sciences Innovations, with several new board members joining. - Since founding in 2021, Odyssey has built an integrated drug discovery platform and moved its first internally discovered program through multiple clinical milestones in just over two years.
